11/18/2013

Catabasis Pharmaceuticals has raised $32 million in its latest funding round and hired former JSB-Partners adviser Ian Sanderson to become its new chief financial officer. The Cambridge, Mass.-based firm said the money will be used for the midstage trials of its hypertriglyceridemia drug candidate CAT-2003.

Related Summaries